NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market on Wednesday that revenues in the fourth quarter increased 13 percent year over year as the firm beat the consensus analyst estimates on the top and bottom lines.

The Mountain View, Calif.-based molecular diagnostic test development firm took in $60.4 million in revenues for the three months ended Dec. 31, 2012, compared to $53.4 million a year ago, topping the average Wall Street estimate of $58.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.